Literature DB >> 8245481

Analysis of glomeruli-eluted Gp330 autoantibodies and of Gp330 antigen of Heymann nephritis.

S P Makker1.   

Abstract

UNLABELLED: Quantity, charge, IgG isotype, Ag reactivity of glomerular gp330 autoantibodies (gp330Ab), and the charge of the putative Ag, gp330, were studied in active Heymann nephritis. Gp330 was anionic with an isoelectric point of 4.6. Despite variation in C3 glomerular immunofluorescence staining, C5b-9 staining was seen in all rats. Positive correlation was seen between glomerular gp330Ab and abnormal 24-h proteinuria (r = 0.637, p = 0.008), which appeared to require a certain threshold level of gp330Ab. Positive correlation was also seen between serum and glomerular gp330Ab at time of death (r = 0.55, p < 0.05). No differences were seen in charge, IgG isotypes of glomerular gp330Ab, or reactivity to gp330 by Western analysis in rats with or without abnormal proteinuria. Comparison of gp330Ab IgG isotypes in immune sera and glomeruli showed no difference in IgG1 and IgG2a, but IgG2b was significantly lower in glomeruli (p < 0.0001).
CONCLUSIONS: 1) this is the first documentation that gp330 is highly anionic; 2) regardless of the degree of proteinuria, all immunized rats deposit in their glomeruli a qualitatively similar type of gp330Ab (charge, IgG isotype, complement activation, gp330 reactivity); 3) despite the highly anionic nature of gp330, anionic gp330Ab accumulate in glomeruli; and 4) complement activation appears to occur in every rat with gp330Ab in glomerulus and development of proteinuria is dependent on a certain threshold level of gp330Ab in the glomerulus which, in turn, correlates with the serum level of gp330Ab.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8245481

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

Review 1.  Idiopathic membranous nephropathy: an autoimmune disease.

Authors:  Sudesh P Makker; Alfonso Tramontano
Journal:  Semin Nephrol       Date:  2011-07       Impact factor: 5.299

Review 2.  Regaining tolerance to a self-antigen by the modified vaccination technique.

Authors:  Arpad Zsigmond Barabas; Chad Douglas Cole; Rene Lafreniere; Donald Mackay Weir
Journal:  Clin Rev Allergy Immunol       Date:  2013-10       Impact factor: 8.667

3.  T cell lines specific for a synthetic Heymann nephritis peptide derived from the receptor-associated protein.

Authors:  H Wu; G Y Zhang; J F Knight
Journal:  Clin Exp Immunol       Date:  2000-07       Impact factor: 4.330

4.  Evidence that epithelial glycoprotein 330/megalin mediates uptake of polybasic drugs.

Authors:  S K Moestrup; S Cui; H Vorum; C Bregengård; S E Bjørn; K Norris; J Gliemann; E I Christensen
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

5.  Presence of immunoglobulin M antibodies around the glomerular capillaries and in the mesangium of normal and passive Heymann nephritis rats.

Authors:  Arpad Z Barabas; Chad D Cole; Arpad D Barabas; Jord M Cowan; Chang Soon Yoon; David M Waisman; Rene Lafreniere
Journal:  Int J Exp Pathol       Date:  2004-10       Impact factor: 1.925

6.  Induction of Heymann nephritis with a gp330/megalin fusion protein.

Authors:  R Raychowdhury; G Zheng; D Brown; R T McCluskey
Journal:  Am J Pathol       Date:  1996-05       Impact factor: 4.307

7.  Transcription and translation of gp600 and receptor-associated protein (RAP) in active Heymann nephritis.

Authors:  S P Makker; R Widstrom; J Huang
Journal:  Am J Pathol       Date:  1995-06       Impact factor: 4.307

8.  Inhibition of complement regulation is key to the pathogenesis of active Heymann nephritis.

Authors:  B Schiller; C He; D J Salant; A Lim; J J Alexander; R J Quigg
Journal:  J Exp Med       Date:  1998-10-05       Impact factor: 14.307

9.  Permanent CD8(+) T cell depletion prevents proteinuria in active Heymann nephritis.

Authors:  M J Penny; R A Boyd; B M Hall
Journal:  J Exp Med       Date:  1998-11-16       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.